Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of fexuclue tab. in patients with acute or chronic gastritis

Conditions: Gastritis

Summary: this study aims to evaluate the efficacy of fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (pros), by comparing assessments before and after treatment.

in this observational study, patient-reported data will be collected using an electronic application (e-pro). the survey on subjective symptoms will be administered twice-once before and once after the administration of fexuclue tablets. additionally, a survey on medication convenience will be conducted once at 2 weeks (up to a maximum of 4 weeks) post-administration. at the same time point (2 to 4 weeks after administration), patients will self-assess their overall improvement through the e-pro application. investigators will also evaluate final improvement based on clinical judgment in a real-world setting and record the outcome in the case report form (crf).

Eligibility criteria:
inclusion criteria: * adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent. * subjects who are scheduled to receive fexuclu tablets (fexuprazan) in accordance with the approved indication. * subjects who present with at least one subjective symptom requiring medical treatment * subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data. exclusion criteria: * individuals who fall under any contraindications for the administration of fexuclu tablets (fexuprazan) as specified in the approved labeling. * individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.

Keywords: acute chronic
a study of isis 2922 in the treatment of advanced cytomegalovirus retinitis

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: the purpose of this study is to compare the safety and effectiveness of two dosage schedules for isis 2922 in the treatment of advanced cytomegalovirus (cmv) retinitis

this is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules of isis 2922.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * oral ganciclovir. * leukocyte growth factors (gm-csf and g-csf) for patients with febrile neutropenia. patients must have: * documented aids. * clinical diagnosis of advanced cmv retinitis in 1 or both eyes. * \>= 2 previous induction courses with anti-cmv retinitis therapy licensed by a regulatory agency. * \> 25% retinal involvement with cmv retinitis. * baseline cmv retinitis lesions which have leading edges \> 1000 micrograms from the macula or optic disk. prior medication: required: * \>= 2 previous induction courses with anti-cmv retinitis therapy licensed by a regulatory agency. allowed: * all anti-cmv therapies other than ganciclovir must be discontinued no less than 2 days prior to entry. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * external ocular infection in the eye to be treated. * other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other disease of the fundus that would preclude assessment of cmv retinitis in the eye to be treated. * ocular conditions that will obstruct visualization of the posterior ocular structures on the eye to be treated. * retinal detachment in the eye to be treated. * ganciclovir implant in the eye to be treated. * known or suspected allergy to phosphorothioate oligonucleotides or intolerance of isis 2922. * silicone oil in the eye to be treated. * pseudoretinitis pigmentosa. * syphilis. patients with the following prior conditions are excluded: * history of surgery to correct retinal detachment in the eye to be treated. * history of syphilis. 1. systemic anti-cmv therapies other than oral ganciclovir. * mellaril, stelazine, chlorpromazine and clofazimine. * combination use of ethambutol and fluconazole. * investigational medications and/or procedures for the treatment of cmv retinitis in the eye to be treated. * ganciclovir implant delivery device in the eye to be treated. * ganciclovir other than oral. * foscarnet.

Keywords: aids-related opportunistic infections antiviral agents drug administration schedule cytomegalovirus retinitis fomivirsen vitreous body
respiratory muscle function in copd exacerbations

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: there is evidence that noninvasive mechanical ventilation (niv) is effective in the treatment of severe exacerbations of copd presenting respiratory acidosis. the aim of the study is to evaluate the benefit of adding niv to conventional treatment in patients with copd exacerbation and hypercapnic respiratory failure without acidosis requiring hospital admission. it is known that niv improves respiratory mechanics, so the primary outcome will be respiratory muscle function. all patients admitted to the hospital for copd exacerbation and hypercapnic respiratory failure without acidosis will be included for a period of 12 months. the patients will be randomized into two groups (conventional treatment or conventional treatment plus niv). clinical data, blood gases, muscle strength parameters will be collected at the inclusion time and 24h after starting niv. quality of life and hospital stay will be measured at discharge. all patients will be followed for a year.


Eligibility criteria:
inclusion criteria: * diagnosis of copd according to international guidelines ( gold) * copd exacerbation requiring hospitalization * initial blood gases: paco2\> 50 mm hg and ph\> 7.35. * if the patient does not have copd diagnosis at the time of inclusion, it could be included if the diagnosis is confirmed within three months after the exacerbation. exclusion criteria: * patients with a ph below 7.35 * patients with intubation criteria * other chronic respiratory diseases (fibrothorax, cystic fibrosis, significant ribcage alterations) * neuromuscular diseases * significant associated chronic systemic diseases (severe liver disease, chronic renal failure requiring dialysis, severe heart disease and active neoplasia) * copd exacerbation secondary to pulmonary embolism, pneumonia or pneumothorax * patients in active treatment with cpap or home ventilation
perception of stressful social stimuli after trauma exposure.

Conditions: Post-traumatic Stress Disorder

Summary: post-traumatic stress disorder is associated with altered processing of sensory stimuli. the clinical phenotype ptsd has predominantly been described for the visual and auditory sensory modalities. however, ptsd symptoms such as intrusive memories are often evoked by olfactory and tactile cues in the environment. moreover, little is known about whether aberrant responses to social olfactory and tactile stimuli are also present in a subclinical population.the purpose of this study is to compare trauma-exposed subjects (e.g. childhood maltreatment) with non-exposed controls in the processing of olfactory and tactile stimuli. this sensory characterizations hold potential to identify potential biomarkers for the course of trauma-related disorders and to inform trauma therapies focusing on sensory integration.


Eligibility criteria:
inclusion criteria: * signed informed consent * subjects that have experienced a traumatic event that meets the dsm-5 criteria exclusion criteria: * schizophrenia, schizoaffective or other psychotic disorder * neurological disorders * psychotropic medication * subjects suffering from a respiratory tract infection or other respiratory disorder known to affect olfactory functioning at investigator's discretion * subjects with anosmia or other previous primary olfactory dysfunction (olfactory threshold score using the "sniffin' sticks" ≤ 5) * dermatitis of the extremities or other skin disorders that affect the skin sensitivity of the extremities
selective aspiration thrombectomy in stemi

Conditions: ST Elevation Myocardial Infarction

Summary: patients who were diagnosed with st-elevation myocardial infarction (stemi) and received primary percutaneous coronary intervention (ppci) from july 2009 to december 2011 were identified from the national health insurance research database of taiwan. the investigators compared the 1-year outcomes of patients with stemi who received aspiration thrombectomy during ppci vs. those who received ppci alone.

data source and study population using the national health insurance research database of taiwan, stemi patients from july 2009 to december 2011 who received aspiration thrombectomy during ppci were defined as the thrombectomy group, and the remaining patients were defined as the pci alone group. icd-9-cm codes were used to identify underlying comorbidities. data regarding the prescription of in-hospital and outpatient medications and the utilization of medical devices were also extracted from the nhird using icd-9-cm procedure codes and pharmacology and device codes. study outcomes the primary endpoints of this study were all-cause mortality and stroke during hospitalization and at 30 days and 1 year of follow-up. ischemic and hemorrhagic subtypes of stroke were further identified according to icd-9-cm codes. all patientswere followed for 1 year or until the outcomes were achieved, whichever came first. statistical analysis propensity score weighting was used to reduce potential differences between the two study groups. the incidence rates of all-cause mortality and stroke were estimated as the total number of events during the follow-up period divided by the person-months at risk. for all-cause mortality, a cox proportional hazard model was used to obtain hazard ratios (hrs). for stroke, fine and gray's competing-risk regression was used to obtain sub-hazard ratios (shrs). the cumulative incidence of stroke versus follow-up time was plotted rather than the event-free rate, because cumulative incidence function can take the competing risk of death into account. for the thrombectomy group, 95% confidence intervals (cis) of the hrs and shrs were calculated using the pci alone group as the referent group.

Eligibility criteria:
inclusion criteria: * patients with st elevation myocardial infarction exclusion criteria: * missing data on sex or discharge date * aged less than 18 years * previous stroke * patients receiving thrombolytic therapy * patients who did not undergo ppci

Keywords: st-elevation myocardial infarction thrombectomy mortality stroke physician volume
effects of blood flow restriction training with low intensity exercises in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of the study is to examine the effects of blood flow restriction training(bfrt) with low intensity exercises on pain, range of motion and quality of life in knee osteoarthritis. a randomized clinical trial will be conducted at lahore general hospital. non-probability convenience sampling will be used, and 36 subjects, age 40-65 years will be randomly allocated into two groups by lottery method after meeting the inclusion criteria.

the aim of the study is to examine the effects of blood flow restriction training(bfrt) with low intensity exercises on pain, range of motion and quality of life in knee osteoarthritis. a randomized clinical trial will be conducted at lahore general hospital. non-probability convenience sampling will be used, and 36 subjects, age 40-65 years will be randomly allocated into two groups by lottery method after meeting the inclusion criteria. both groups will receive ultrasound therapy for 7 minutes, as common treatment. group a will be treated with blood flow restriction training with low intensity exercises and group b will be treated with baseline treatment only. 3 sessions per week and total 12 sessions for 4 weeks. the outcome measures will be conducted through nprs, womac index for osteoarthritis,kellgren and lawrence scale and goniometry before and after 4 weeks. data will be analyzed using spss software version 26.

Eligibility criteria:
inclusion criteria: * both male and female age between 40 to 65 years diagnosed with womac ostearthritis index having acute knee pain. * patients with history of osteoarthritis (of grade 1 and 2 with kl(kellgren and lawerence)) grading system for knee osteoarthritis * pain in and around knee measuring through numeric pain rating scale(nprs)\>4(14) exclusion criteria:patient with history of * hypertension * diabetes * sickle cell anemia * renal compromise * obesity * open fracture, * increased intracranial pressure * pregnancy * cancer or tumor, * extremity with dialysis access, * extremity fracture * peripheral vascular compromise * dvt(deep vein thrombosis) \& pulmonary embolism deformity of hip \& back

Keywords: blood flow restriction training knee osteoarthritis pain quality of life range of motion
the effect of preoperative stoma simulation on anxiety and postoperative adaptation

Conditions: Colostomy - Stoma; Ileostomy - Stoma

Summary: the majority of patients (60-70%) develop high levels of anxiety before surgery. surgical patients may experience feelings of anxiety due to insufficient information and counseling before surgery and potential changes in the body caused by surgery. fears include (but are not limited to) not waking up from anesthesia, not being able to return to previous work and family life, and adaptation concerns regarding new processes after surgery. patients with fear of complications experience preoperative anxiety four times more than other patients. other factors affecting preoperative anxiety were determined to be waiting for a long time before surgery, not knowing what will happen during surgery, losing control of the body, not receiving sufficient social support, being exposed to medical errors, and encountering undesirable health outcomes after surgery. the changes that will occur in the body and lifestyle after stoma surgery scare patients and cause them to feel anxiety in the pre-operative period. despite significant developments in stoma care products and the increase in the number of nurses specialized in stoma care in recent years, the majority of patients experience problems with compliance. for this reason, the compliance of stoma patients with stoma life is increasingly the subject of clinical trials and epidemiological studies. in our country, studies conducted to determine the problems experienced by stoma individuals regarding compliance with stoma and social life are limited. nursing interventions are recommended to reduce patients' anxiety and increase their compliance with stoma after surgery. this study aims to evaluate the effect of stoma simulation performed preoperative surgery on the patient's anxiety level and postoperative stoma compliance.


Eligibility criteria:
inclusion criteria: * all patients who are planned for elective stoma surgery, * are between the ages of 18-65, * can speak turkish, * can read and write, * are conscious, * are willing to participate in the study will be included. exclusion criteria: * patients with speech or hearing impairments, * those who have had urostomy surgery, * those who have a psychological diagnosis or are taking medication, * those who need intensive care after surgery, * those whose stoma was closed during the study, * those who have complications in the peristomal area, * patients who have had stoma surgery before will be excluded from the study.
epo906 therapy in patients with advanced colorectal cancer

Conditions: Colorectal Neoplasms; Colonic Neoplasms

Summary: this study will examine whether the new investigational drug epo906, given by intravenous infusion (iv directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.


Eligibility criteria:
inclusion criteria patients must meet the following criteria to be eligible for the study: * histologically or cytologically documented evidence of colorectal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) * the patient should have failed or progressed on no more than two prior chemotherapies for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine and either irinotecan or oxaliplatin, or any combination of these agents, with the last chemotherapy having contained irinotecan or oxaliplatin) * patients who have received only adjuvant therapy for their disease are eligible, as long as they have relapsed within six months of completing such therapy and that therapy contained 5-fu and irinotecan or oxaliplatin administered in combination as part of an investigational protocol * must have a life expectancy of greater than three (3) months. exclusion criteria the following patients are not eligible for the study: * patients with symptomatic cns metastases or leptomeningeal involvement * patients with unresolved bowel obstruction * patients with any peripheral neuropathy or unresolved diarrhea greater than grade 1 * patients with severe cardiac insufficiency * patients who have undergone major surgery for any cause less than 4 weeks prior to study entry * patients with radiation therapy or chemotherapy within the last four weeks * patients taking coumadin or other warfarin-containing agents with the exception of low dose coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports * history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ * patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae * hiv+ patients * pregnant or lactating females

Keywords: colon rectum colorectal rectal cancer tumor tumour neoplasm carcinoma intravenous epothilone
in vivo arthroscopic behavior of the infrapatellar plica of the knee

Conditions: Anterior Knee Pain Syndrome

Summary: anterior knee pain has been an enigmatic problem for orthopedic surgeons. recent studies, as well as the clinical observation of the principle investigator have suggested that arthroscopic resection of the infrapatellar plica (ipp), a vestigial remnant from embryonic development of no known clinical or biological significance, may eliminate this pain. the mechanism whereby this pain is related to the ipp is unclear. this study will document the mechanical behavior of the ipp, its kinematics, as recorded on video among a group of subjects who are undergoing arthroscopy. radiographic visualization of the observed behavior will be obtained by injection of contrast material, and then fluoroscopic recording of a standard series of motions. the plica will then be resected to avoid any possibility of residual symptoms related to its presence. further fluoroscopy of the knee without plical attachment, will allow the kinematic behavior to be assessed. the procedure will then be terminated.

the infrapatellar plica (ipp) of the human knee is vestigial remnant of the embryologic division between the medial and lateral compartments of the knee, present in 85.5% of knees1, felt by some to be of no clinical significance other than acting as a block to visualization an movement during arthroscopy.2 s.j. kim 3,4, c.r. boyd 5, and b. demirag 2006 have documented successful relier of anterior knee pain after resection of the ipp. this study seeks to assess the relationship between knee motion, activation of the extensor apparatus, and the ipp, in essence, the kinematics of the contents of the anterior compartment of the knee. the hypothesis to be evaluated is: the infrapatellar plica is a structure of fundamental biomechanical significance, allowing the transmission of force from the extensor apparatus to the distal femur through the fat pad, and acting as a restraint and a modulator of fad pad mobility. subjects will be identified by the pi at their office visit. the subject will be consented. the consent will be discussed and verified in a second office visit before surgery. the subject will undergo arthroscopy specifically directed toward identifying and treating known pathology. once this is finished, if an ipp is present, it will be injected with radiographic contrast material. a series of maneuvers will be performed involving passive and active motion of the knee and active contraction of the quadriceps apparatus. videotape recording and fluoroscopy will be undertaken. the plica will be removed. another fluoroscopy will be performed. the patient will be followed according to the standard practice for arthroscopy and the defined pathology.

Eligibility criteria:
must be healthy subject must be \>18 years of age, skeletally mature must bepending knee joint arthroscopy. may not have active infection

Keywords: knee physiology anterior compartment knee infrapatellar plica ligamentum mucosum enthesis organ fat pad of the knee patellofemoral kinematics
coaching and prehabilitation: faisability study in patients with acute myeloid leukemia and myelodysplastic syndrome

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: this faisability study aims to evaluate the adhesion of the patient to a multidisciplinary program (adapted physical activity, coaching and nutrition)


Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia or high-risk myelodysplastic syndrome * age between 18 and 70 years * eligible for an intensive chemotherapy * eligible for allograft * able to answer a questionnaire exclusion criteria: * diagnosis of acute promyelocytic leukemia * palliative treatment * contraindication to moderate physical activity * performans status 4, unless it is related to the disease * patient who does not understand french * patient unable to use a smartphone * patient deprived of liberty or placed under the authority of a tutor, * patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.

Keywords: prehabilitation coaching nutritional support physical activity allogeneic stem cells transplantation
efficacy of tegaserod in relieving the symptoms of female patients with irritable bowel syndrome (ibs), excluding those with predominant diarrhea ibs

Conditions: IBS-C and IBS With Mixed Bowel Habits

Summary: recent literature has demonstrated that the group of ibs sufferers who experience mixed bowel habits may be more similar to ibs-c patients than ibs-d patients. this study will evaluate the efficacy and safety of tegaserod 6 mg b.i.d. in women with ibs and mixed bowel habits, excluding those with predominant diarrhea.


Eligibility criteria:
inclusion criteria: * women, outpatients, 18-65 years of age with ibs-c or ibs with mixed bowel habits * in the 12 months preceding study entry, they had to have at least 12 weeks (not necessarily consecutive) of abdominal discomfort/pain with 2 out of 3 features: 1) relieved with defecation; 2) onset associated with a change in stool frequency; 3) onset associated with a change in form (appearance) of stool. * had to fulfill the following criteria (ibs questionnaire) during the last 3 months prior to study entry: abdominal discomfort or pain present during at least 3 weeks in the last 3 months, and at least two of the following: abdominal discomfort or pain gets better or stops after a bowel movement; change in bowel movement frequency when the abdominal discomfort or pain starts; change in bowel movement consistency when the abdominal discomfort or pain starts exclusion criteria: * ibs-d * not reporting any constipation and diarrhea criteria * evidence of structural abnormality of the gastrointestinal tract or diseases/conditions that affect bowel transit * history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions * evidence of cathartic colon or history of laxative abuse other protocol-defined inclusion/exclusion criteria may apply.

Keywords: tegaserod, ibs-c, women, mixed bowel habit